Lauren P. Silvernail, CFO, Secretary & EVP Corporate Development at Revance Therapeutics, Inc. (RVNC), bought 980 shares at $17.74 ($17K) on 2014-12-11, disclosed to the SEC on 2014-12-15.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $17.73 | 200 | $4K | 20.4% |
| 2 | $17.74 | 780 | $14K | 79.6% |
| Total | $17.74 avg | 980 | $17K | 100% |
| Filing → |
| EOLS | SELL | 2022-03-10 | $198K | — | Filing → |
| EOLS | SELL | 2021-08-12 | $320K | — | Filing → |
| EOLS | SELL | 2021-01-26 | $20K | — | Filing → |